Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes

Clinical Infectious Diseases

Volumn 59, Issue 6, 2014, Pages 905-907

  Rhodes, Nathaniel J ^a,b   MacVane, Shawn H ^c   Kuti, Joseph L ^c   Scheetz, Marc H ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CREATININE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC THERAPY; BODY WEIGHT; CONTINUOUS INFUSION; CREATININE CLEARANCE; LETTER; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SEPTIC SHOCK; BACTERIAL INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMAN; MALE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE;

EID: 84907060557     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu402     Document Type: Letter

References (10)

1. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically Ill patients? Clin Infect Dis 2014; 58:1072-83.
2. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter doubleblind, randomized controlled trial. Clin Infect Dis 2013; 56:236-44.
3. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
4. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
5. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045-53.
6. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49:461-3.
7. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54:460-5.
8. Patel N, Scheetz MH, Drusano GL, Lodise TP. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. J Antimicrob Chemother 2010; 65:2285-90.
9. Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit 2012; 34:467-76.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. M100-S24. Wayne, PA: Clinical and Laboratory Standards Institute, 2014.